TSCAN THERAPEUTICS, INC. (TCRX) Current Ratio
- Current ratio · latest quarter: Value 3.37×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.37× | Current assets / current liabilities. $104.40M ÷ $30.96M ≈ 3.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 104.40M USD | Assets, Current |
| Current obligations | 30.96M USD | Liabilities, Current |
| Cash and equivalents | 100.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 3.12M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 11.71M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $104.40M | $30.96M | $100.16M | (m) | (m) | (m) | $3.12M | $11.71M | 3.37× |
| 2026-03-31 | $132.77M | $19.97M | $128.06M | (m) | (m) | (m) | $2.30M | (m) | 6.65× |
| 2025-12-31 | $157.21M | $18.70M | $152.41M | (m) | (m) | (m) | $1.24M | (m) | 8.41× |
| 2025-09-30 | $188.16M | $29.21M | $169.51M | $14.95M | (m) | (m) | $6.35M | (m) | 6.44× |
| 2025-06-30 | $221.13M | $31.32M | $169.39M | $48.65M | (m) | (m) | $4.54M | (m) | 7.06× |
| 2025-03-31 | $254.84M | $29.82M | $154.11M | $97.58M | (m) | (m) | $4.97M | (m) | 8.55× |
| 2024-12-31 | $292.72M | $35.96M | $178.69M | $111.42M | (m) | (m) | $4.28M | (m) | 8.14× |
| 2024-09-30 | $274.08M | $28.66M | $133.12M | $138.00M | (m) | (m) | $3.65M | (m) | 9.56× |
| 2024-06-30 | $299.53M | $38.57M | $242.16M | $55.52M | (m) | (m) | $3.11M | $10.34M | 7.77× |
| 2024-03-31 | $164.72M | $31.48M | $140.51M | $22.27M | (m) | (m) | $2.12M | $6.80M | 5.23× |
| 2023-12-31 | $194.24M | $29.82M | $133.36M | $58.69M | (m) | (m) | $2.37M | $3.35M | 6.51× |
| 2023-09-30 | $217.57M | $33.15M | $155.19M | $60.23M | (m) | (m) | $3.20M | $1.11M | 6.56× |
| 2023-06-30 | $242.22M | $35.12M | $208.84M | (m) | $31.93M | (m) | $3.39M | (m) | 6.90× |
| 2023-03-31 | $100.91M | $14.05M | $95.61M | (m) | (m) | (m) | $2.77M | (m) | 7.18× |
| 2022-12-31 | $124.13M | $17.30M | $120.03M | (m) | (m) | (m) | $2.91M | (m) | 7.17× |
| 2022-09-30 | $141.18M | $16.59M | $137.31M | (m) | (m) | (m) | $2.71M | (m) | 8.51× |
| 2022-06-30 | $129.36M | $17.17M | $125.60M | (m) | (m) | (m) | $3.10M | (m) | 7.53× |
| 2022-03-31 | $145.75M | $18.46M | $140.84M | (m) | (m) | (m) | $2.89M | (m) | 7.89× |
| 2021-12-31 | $165.65M | $21.34M | $161.41M | (m) | (m) | (m) | $1.76M | (m) | 7.76× |
| 2021-09-30 | $187.00M | $22.94M | $182.31M | (m) | (m) | (m) | $5.07M | (m) | 8.15× |
| 2021-06-30 | $110.07M | $20.62M | $106.20M | (m) | (m) | (m) | $3.55M | (m) | 5.34× |
| 2020-12-31 | $36.45M | $17.45M | $34.79M | (m) | (m) | (m) | $2.91M | (m) | 2.09× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |